CART Targeting of Solid Tumors: More Pieces to the Puzzle.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29348296.
- Also identified by DOI 10.1158/1078-0432.CCR-17-3432.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor-modified T (CART)-cell-based targeting of solid tumors remains a considerable and worthwhile challenge in the field of immunotherapy. The role of chemotherapy to target stroma and enhance chimeric antigen receptor (CAR) cell antitumor function, expansion, and persistence is still unresolved. <i>Clin Cancer Res; 24(6); 1246-7. ©2018 AACR</i><i>See related article by Guo et al., p. 1277</i>.
Medical subject headings
- Biliary Tract Neoplasms
- Receptors, Chimeric Antigen